Greater Cannabis Company (GCAN) Non-Current Debt (2020 - 2023)
Greater Cannabis Company's (GCAN) quarterly Non-Current Debt came in at $36000.0 in Q3 2023, down 73.33% year-on-year from $135000.0 in Q3 2022, and down 73.33% quarter-over-quarter from $135000.0 in Q3 2022.
Greater Cannabis Company (GCAN) Non-Current Debt (2020 - 2023) Analysis & Trends
Greater Cannabis Company's Non-Current Debt history runs 4 years deep, the most recent figure standing at $36000.0 for Q3 2023.
- On a quarterly basis, Non-Current Debt fell 73.33% year-over-year to $36000.0 in Q3 2023; TTM through Sep 2023 was $36000.0, a 73.33% decrease from a year earlier, with the FY2020 full-year figure at $325212.0, changed N/A from the prior year.
- Non-Current Debt slipped to $36000.0 in Q3 2023 per GCAN's latest filing, from $135000.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $325212.0 in Q4 2020 and bottomed at $22500.0 in Q1 2021.
- The 4-year median for Non-Current Debt is $101041.0 (2020), against an average of $142074.4.
- Across the five-year window, Non-Current Debt tumbled 86.39% in 2021 and rose 11.11% in 2022, its largest moves.
- Year by year, Non-Current Debt stood at $325212.0 in 2020, then dropped by 4.35% to $311050.0 in 2021, then tumbled by 56.6% to $135000.0 in 2022, then tumbled by 73.33% to $36000.0 in 2023.
- Per Business Quant, the three latest GCAN Non-Current Debt figures stand at $36000.0 (Q3 2023), $135000.0 (Q3 2022), and $25000.0 (Q2 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 36,000.00 |
| Sep 30, 2022 | 135,000.00 |
| Jun 30, 2022 | 25,000.00 |
| Sep 30, 2021 | 311,050.00 |
| Jun 30, 2021 | 22,500.00 |
| Mar 31, 2021 | 22,500.00 |
| Dec 31, 2020 | 325,212.00 |
| Sep 30, 2020 | 311,050.00 |
| Jun 30, 2020 | 67,082.00 |
| Mar 31, 2020 | 165,350.00 |